Health Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chinese University of Hong Kong
Recent findings illuminate research in oncology
March 22nd, 2005
Investigators in the People's Republic of China, Germany and Turkey have published new oncology data. Study 1: Lamivudine prevents hepatitis B reactivation during breast cancer therapy. According to recent research published in the journal Breast Cancer Research and Treatment, "in parts of Asia, about 10% of the population have chronic hepatitis B virus (HBV) infection, and cancer patients who are HBV carriers are frequently complicated by HBV reactivation while receiving cytotoxic chemotherapy." "The condition may result in varying degrees of liver damage, causing disruption in chemotherapy and compromising the patients'...
Source: Health Risk Factor Week (2005-03-22)
|
